This pumpkin bread was such a huge hit on my Thanksgiving table years ago, that my family begins asking for it as soon as Fall begins.
I serve it with various jams, jellies and honey butter on my brunch tables too.
For those facing the challenging diagnosis of ALK-positive lung cancer, brain metastases often pose a serious concern. Research reveals that up to 40% of these patients have brain metastases right from the start. This sets the stage for a critical question in treatment planning: Is it better to tackle these brain metastases with spot radiation, or stereotactic radiosurgery (SRS)
Read More
If you think you don’t like eggplant this will change your mind.
This recipe has all the feels. Warm, cheesy, melty, straight from the oven. I make it with any ground meat I have on hand.
What’s also nice is that it’s baked and not fried. So you can have that second helping. You’ll want it.
Suzanne Houssainy was unanimously chosen by the Board of ALK Positive, Inc. for the role among over 300 candidates, many of whom were truly exceptional. We feel that the long, solid experience and professionalism Suzanne brings to the table is going to help our organization get to the next level. Suzanne has over 25 years of experience in sales, management and leadership positions in both the for-profit and the nonprofit worlds
Read More
Team members of the Judith Tam ALK Lung Cancer Research Initiative ventured out to Nashville on July 18th for the 2024 ALK Positive Summit, to embark on an unprecedented research blood collection which took place July 19th and 20th. This was the culmination of 5 months of intense visioning with ALK Positive, Inc and sculpting of every detail of the whole process.
Read More
Matt and Stephanie Mcavin were recently featured in Genentech’s Biomarker Testing Campaign that was filmed during the ALK Summit in Nashville. We interviewed them about their story living with an ALK+ cancer diagnosis, juggling Matt’s diagnosis with caring for their family of three teenagers, and their advocacy in getting the word out on the importance of biomarker testing.
Read More
ATLANTA, GEORGIA, 30 JULY 2024 – ALK Positive, in collaboration with 23andMe Holding Co., a leading genetic health and biopharmaceutical company, and 20 lung cancer advocacy organizations, today announces a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection.
Read More
A cold tomato-based soup originating from the Andalusia region of Spain, Gazpacho is as fun to say as it is to make. A mixed medley of vegetables and herbs, it carries numerous health benefits too!
My recipe is a bit of a cheat…because you don’t need a peeler, and barely a knife, and that's only to add garnish at the end.
Read More
We interviewed Amanda Bialack-Stewart about her unusual story with ALK+ lung cancer (having been diagnosed right after giving birth to twins at the age of 36), how she manages to balance family, work, fun, and self-care as a patient, and her active involvement in ALK Positive, Inc through creating and leading the Young ALKies Group.
Read More
Those of us lucky enough to have Dr. Camidge as part of our care team have been encouraged to follow these tumor markers. Colin Barton, founder of the ALK Positive Medical Committee, has been doing so since 2018. LabCorp currently tests for these markers as part of my regular blood draws, and insurance pays for it. Presumably other diagnostic and insurance companies will do the same. The four markers are CEA (carcinoembryonic antigen/colorectal cancer), CA125 (ovarian), CA19.9 (pancreatic), and CA27.29 (breast).
Read More
ALK Positive, Inc has introduced a section in our newsletter to feature international (non-US) ALK patient groups/organizations. If you would like your group/organization to be featured in a future newsletter, please contact Duncan Preece at duncan.preece@alkpositive.org
In this issue, we are introducing ALK Positive Italia and have interviewed the founder, Patty Saccenti.
Read More
Clinical trials are the gold standard for evaluating new treatments in medicine. They offer a structured approach, where patient groups are carefully selected, treatments are administered, and results are meticulously followed over time. This controlled environment allows for a deep understanding of how treatments perform in specific patient populations, free from the confounding factors that might skew results.
Read More
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to a special series on “ALK-positive NSCLC” for the Translational Lung Cancer Research (TLCR) journal.
Read More
Can you share with our readers the founding story of the ALK Positive Australia? What inspired the establishment of the organisation.
I, like many others, including the other founders, felt at initial diagnosis that it was difficult to find local, relevant information about ALK+ Lung Cancer and I was dubious of heading to Facebook for answers. Australia unfortunately does not have a dedicated Lung Cancer body despite Lung Cancer remaining the cancer with the highest mortality rate of all cancers in the country. Instead, we have Cancer Australia, Lung Foundation Australia, Cancer Council Australia and Rare Cancers Australia.
Read More
This trial is for patients with Stage 4 ALK positive NSCLC that have progressed on an earlier generation ALK TKI AND lorlatinib, and on any number of other standard-of-care or trial treatments. The trial drug is gilteritinib (aka Xospata), which was approved by the FDA in 2018 for a type of leukemia, but has been shown to have activity against ALK NSCLC in patient-derived models (mice with transplanted human cancer).
Read More
When we think of Superfoods, chickpeas are not necessarily what comes to mind, but chickpeas have many surprising health benefits. They contain important vitamins and minerals (B, B6, folate and vitamin E), they have protein, lots of fiber, and all that fiber may actually keep you feel fuller longer, keeping your weight in check.They are also gut healthy and heart healthy. You can roast them, puree them, and add them to soups and stews.
Read More
CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).
Read More
Marc Muskavitch is an ALK patient, Board member for ALK Positive, Inc., and one of the leading members of the ALK Positive Medical Committee. We interviewed him on his journey with ALK+ lung cancer so far, his work with the Medical Committee, and what most excites him about the future of ALK+ cancer treatments and collaborations to improve outcomes for ALK patients.
Read More
Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with ALK-positive lung cancer.
ALK Positive is the first foundation partner to commit funding to Break Through Cancer for the initiative. Jointly, they hope to inspire other foundations, individual donors, and industry partners to join them as they work to build a coalition to support this life-saving effort.
Read More
In the ever-evolving arena of ALK-positive cancer therapies, clinical trials offer patients not only cutting-edge interventions but also a chance to contribute to the advancement of ALK cancer treatment. In examining international ALK cancer trials, we uncover both challenges and opportunities for those seeking innovative treatments beyond conventional options.
Read More